newsfilter
← Latest News
Business Wire·

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) ("Clovis" or the Company"), a biopharmaceutical company focused on acquiring, developing, and